Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Ruxolitinib can help regrow hair in severe alopecia areata.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

The treatment combination is effective and generally safe for lung cancer.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Sonidegib effectively treated basal cell carcinoma in a patient with lupus without worsening lupus symptoms.

Reducing gefitinib dosage improved hair loss, but scarring remained.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

A new compound shows promise as a topical treatment for hair loss.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Imatinib can cause hair loss due to lichen planopilaris.

Topical Ruxolitinib may safely treat severe hair loss.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Erlotinib can cause hair loss and texture changes.

Entospletinib effectively prevents eye and skin GVHD in mice.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.